EGFR-Mutated Lung Cancer Video Perspectives
Erminia Massarelli, MD, PhD, MS
Massarelli reports receiving honoraria from AstraZeneca and Merck; consulting and/or advising Bristol Myers Squibb Foundation, Genentech/Roche, Janssen Scientific Affairs, Merck, and Sanofi; serving on a speakers' bureau for AstraZeneca; receiving research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Pfizer, and Tessa Therapeutics; and receiving travel, accommodations, and expenses from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, and Pfizer.
VIDEO: Prevalence of EGFR-mutated non-small cell lung cancer
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
EGFR-mutated non-small cell lung cancer account for about 20% of non-small cell lung cancer, and median age is usually about 60, 65 years old. However, especially in areas such as south California, we do see EGFR-mutated non-small cell lung cancer rising also before age 40. And they are more common in Asian women. They're usually associated with no smoking history. So, whenever you see a patient with, you know, who is a never-smoker, I would highly suspect presence of EGFR-sensitizing mutation.
